info@oncologyventure.com

First Patient Dosed in Phase 2 Study of PARP/Tankyrase Inhibitor 2X-121 for Metastatic Breast Cancer

CAMBRIDGE, Mass. and HOERSHOLM, Denmark, June 26, 2018 — Oncology Venture US Inc., Oncology Venture AB (OV:ST) (“OV”) and Medical...

Abstracts on Three Pipeline Products Selected for 2018 ASCO Clinical Meeting

  Phase 1 Study of PARP Inhibitor 2X-121 Selected as Oral Presentation June 1, 2018 Hoersholm, Denmark and Cambridge, MA...

2X Oncology to Participate in Two Upcoming Investor Conferences

  Cambridge, MA – October 25, 2017 — 2X Oncology, Inc. (“2X” or the “Company”), a precision medicine company developing...

2X Oncology Announces Validation of Drug Response Predictor (DRP) for its PARP Inhibitor 2X-121

— Developed DRP Successfully Identified Responders and Non-responders to Treatment with 2X-121 in 13-Patient Blinded Study —  Cambridge, MA – August...

Oncology Venture and Eisai Forge Exclusive Global License Agreement for Clinical Stage Oncology Drug PARP Inhibitor E7449 / 2X-121

2X Oncology to conduct Phase 2 Study of 2X-121 in metastatic breast cancer patients Hoersholm, Denmark, and Cambridge, MA, July...

2X Oncology Obtains Investigational New Drug Application for 2X-111 Glutathione Enhanced PEGylated Liposomal Doxorubicin

Cambridge, MA – June 8, 2017 — 2X Oncology, Inc. (“2X” or the “Company”), a precision medicine company developing targeted...

2X Oncology to Present at Jefferies Global Healthcare Conference

  Cambridge, MA — May 31, 2017 — 2X Oncology, Inc. (“2X” or the “Company”), a company focused on developing...

George O. Elston Named Chief Executive Officer of 2X Oncology

CAMBRIDGE, Mass., May 30, 2017 — 2X Oncology, Inc. (“2X” or the “Company”), a company focused on developing targeted therapeutics...